Aurisco Pharmaceutical Co.Ltd(605116) 16 announced that the company plans to build a new production line with an annual output of 308 tons of characteristic APIs and 200 million anti-tumor preparations in Cangshan industrial cluster, Tiantai.
The announcement shows that according to the biomedical development plan of Tiantai County, Aurisco Pharmaceutical Co.Ltd(605116) combined with the actual situation of the market, in order to realize the long-term development of the enterprise, give play to its own technical and market advantages, expand the export of advantageous APIs, meet the cdmo business needs of customers, expand the preparation market and ensure sufficient production capacity, The company plans to build a new production line with an annual output of 308 tons of characteristic APIs and 200 million anti-tumor preparations in Cangshan industrial agglomeration area, Tiantai.
When interacting with investors, Aurisco Pharmaceutical Co.Ltd(605116) said that the company was mainly engaged in the R & D, production and sales of characteristic API, pharmaceutical intermediates and preparations. The company’s products have passed the approval and certification of who-pq, USFDA, EMA, uk-mhra or are under review. As of December 31, 2020, two API products of the company have passed the GMP inspection in China and three API products have passed the GMP (bgv) inspection abroad; 9 products have obtained the EU export API certificate; Four products have obtained the EU CEP certificate, three products have been registered in India, one product has passed the review of who and one product has passed the review of FDA; 19 products have submitted US DMF documents and 5 products have submitted nmpa documents. Please pay attention to the company’s regular report for the latest data in 2021.
